BIIB stock price relative strength index (RSI) stands at 61, neutral-to-bullish territory, implying there’s still room before overbought conditions. Technical traders may target breakouts above $232 as confirmation of renewed uptrend signals. Related: The U.S. Government Just Shut Down: Here's What It Means for the Economy and Stocks Biogen ( NASDAQ:BIIB - Get Free Report ) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The firm had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.32 billion. During the same period in the previous year, the firm posted $5.28 EPS. The company's quarterly revenue was up 7.3% compared to the same quarter last year. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS. As a group, equities research analysts expect that Biogen Inc. will post 15.83 earnings per share for the current fiscal year. Insider Buying and Selling at Biogen Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche In other Biogen news, insider Priya Singhal sold 517 shares of the business's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the completion of the transaction, the insider directly owned 5,772 shares in the company, valued at approximately $770,850.60. The trade was a 8.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link . Also, insider Rachid Izzar sold 2,223 shares of the business's stock in a transaction on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the completion of the transaction, the insider owned 6,330 shares of the company's stock, valued at $854,550. This trade represents a 25.99% decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders own 0.18% of the company's stock. Institutional Inflows and Outflows Several institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC raised its holdings in Biogen by 15.2% in the 2nd quarter. Corient Private Wealth LLC now owns 34,331 shares of the biotechnology company's stock valued at $4,312,000 after acquiring an additional 4,540 shares during the last quarter. Caldwell Trust Co acquired a new position in Biogen in the 2nd quarter valued at $50,000. Valeo Financial Advisors LLC acquired a new position in Biogen in the 2nd quarter valued at $225,000. Osaic Holdings Inc. grew its stake in shares of Biogen by 12.1% during the 2nd quarter. Osaic Holdings Inc. now owns 8,735 shares of the biotechnology company's stock valued at $1,098,000 after buying an additional 941 shares during the period. Finally, Lavaca Capital LLC increased its holdings in shares of Biogen by 56.8% during the 2nd quarter. Lavaca Capital LLC now owns 447 shares of the biotechnology company's stock worth $56,000 after buying an additional 162 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds. Biogen Company Profile ( Get Free Report ) Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. Featured Stories Five stocks we like better than Biogen Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness Lamb Weston: Is the King of Spuds a Buy or a Dud for 2026? What is a Bond Market Holiday? How to Invest and Trade Palantir Stock Eyes New Highs, Boosted by Boeing Partnership How to Choose Top Rated Stocks Marvell Soars on +$6B in Buybacks—Can the Recovery Continue? This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]. Should You Invest $1,000 in Biogen Right Now? Before you consider Biogen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list. While Biogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Beginner's Guide To Retirement Stocks Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report A key observation in BIIB stock price trends is the uptick in analyst “buy” ratings, now at 58% consensus versus 52% last month. This improving sentiment aligns with targeted clinical milestone achievements.